BP28920 Phase I study of RO6895882 in solid tumours

• Research type

  Research Study

• Full title

  AN OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMOURS.

• IRAS ID

  145143

• Contact name

  Mark Middleton

• Contact email

  mark.middleton@oncology.ox.ac.uk

• Sponsor organisation

  F Hoffmann-La Roche Ltd

• Eudract number

  2013-003041-41

• Clinicaltrials.gov Identifier

  NCT02004106

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  14/SC/0134

• Date of REC Opinion

  2 Apr 2014

• REC opinion

  Favourable Opinion